Loading...
XSHG
600671
Market cap296mUSD
Dec 05, Last price  
17.23CNY
1D
1.89%
1Q
-7.42%
Jan 2017
-44.08%
Name

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

Chart & Performance

D1W1MN
XSHG:600671 chart
P/E
137.63
P/S
9.66
EPS
0.13
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-6.06%
Revenues
217m
+78.44%
238,707,452259,671,298265,228,863253,978,179245,336,892234,226,890277,265,339229,078,895281,468,861148,727,33894,765,832123,725,458176,382,787358,470,846297,072,374206,627,323147,069,186108,906,179121,778,535217,295,933
Net income
15m
P
3,671,008386,43015,120,9894,079,5180026,439,20702,108,4202,713,42801,217,1847,179,075050,680,106000-38,275,14815,245,827
CFO
0k
P
8,482,67555,387,26847,532,66521,189,1807,583,47500012,372,830653,79001,606,84924,520,31970,706,116161,127,708000-20,428,8200
Dividend
Aug 24, 20050.163768 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, slicing, and powder grinding services, as well as Chinese medicine diagnosis and treatment services. In addition, the company engages in the software development, remote health management, commercial complex management, food, Internet information businesses, etc. Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd was founded in 1958 and is headquartered in Hangzhou, China.
IPO date
Aug 23, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT